Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Pipeline Review, H2 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 52

Note*:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Global Markets Direct's, ‘Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Pipeline Review, H2 2016', provides in depth analysis on Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted pipeline therapeutics.

The report provides comprehensive information on the Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)

  • The report reviews Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics and enlists all their major and minor projects

  • The report assesses Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news and deals related to Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand the targeted therapy areas and indications for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Overview 7
Therapeutics Development 8
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Products under Development by Stage of Development 8
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Products under Development by Therapy Area 9
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Products under Development by Indication 10
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Products under Development by Companies 13
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Products under Development by Universities/Institutes 15
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 21
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Companies Involved in Therapeutics Development 22
Advinus Therapeutics Ltd 22
Amgen Inc. 23
Astellas Pharma Inc. 24
Caldan Therapeutics Limited 25
Connexios Life Sciences Pvt. Ltd. 26
Daiichi Sankyo Company, Limited 27
Hyundai Pharmaceutical Co., Ltd. 28
Japan Tobacco Inc. 29
Jiangsu Hengrui Medicine Co., Ltd. 30
Merck & Co., Inc. 31
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Drug Profiles 32
AM-1638 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
AM-3189 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
AM-6226 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
AS-2034178 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
AS-2575959 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
CNX-01167 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
DS-1558 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
HD-6277 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
JTT-851 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
MK-8666 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Small Molecule to Agonize GPR40 and GPR120 Receptors for Type 2 Diabetes - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Small Molecule to Antagonize GPR40 for Obesity - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Small Molecules to Agonize GPR40 for Diabetes - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
TUG-770 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Dormant Projects 47
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Discontinued Products 48
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Featured News & Press Releases 49
Apr 10, 2012: Connexios in discussions to partner early-stage GPR40 diabetes drug, CRO will be chosen in US/EU -CEO 49
Jun 27, 2011: Connexios Life Science Presents Preclinical Data On CNX-011-67 At American Diabetes Association Meeting 49
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 51
Disclaimer 52

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Action, H2 2016 19
Number of Products by Stage and Route of Administration, H2 2016 20
Number of Products by Stage and Molecule Type, H2 2016 21
Pipeline by Advinus Therapeutics Ltd, H2 2016 22
Pipeline by Amgen Inc., H2 2016 23
Pipeline by Astellas Pharma Inc., H2 2016 24
Pipeline by Caldan Therapeutics Limited, H2 2016 25
Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2016 26
Pipeline by Daiichi Sankyo Company, Limited, H2 2016 27
Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016 28
Pipeline by Japan Tobacco Inc., H2 2016 29
Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 30
Pipeline by Merck & Co., Inc., H2 2016 31
Dormant Projects, H2 2016 47
Discontinued Products, H2 2016 48

List of Figures

Number of Products under Development for, H2 2016 8
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Mechanism of Actions, H2 2016 18
Number of Products by Stage and Mechanism of Actions, H2 2016 19
Number of Products by Stage and Routes of Administration, H2 2016 20
Number of Products by Stage and Molecule Type, H2 2016 21
  • Transfection Reagents and Equipment Market by Method (Biochemical (Calcium Phosphate, Lipofection, Dendrimers), Physical (Electroporation, Nucleofection), Viral)), Application (Biomedical, Protein Production), End User - Global Forecast to 2021
    Published: 13-Jan-2017        Price: US 5650 Onwards        Pages: 209
    The global transfection reagents and equipment market is expected to reach USD 1.02 billion by 2021 from USD 715.4 million in 2016, at a CAGR of 7.5% during the forecast period 2016 to 2021. Over the years, the transfection reagents and equipment market has witnessed various technological advancements in equipment as well as reagents to address the requirements of researchers and biotechnology & biopharmaceutical companies. These advancements have led to the development of transfe......
  • Rat Model Market by Model Type (Outbred, Inbred, Knockout), Technology (CRISPR, Micro Injection), Therapeutic Area (Neurology, Oncology), Service (Breeding, Cryopreservation), Care Products (Cages, Feed, Bedding) & End User -Global Forecast to 2021
    Published: 12-Jan-2017        Price: US 5650 Onwards        Pages: 253
    The rat model market is projected to reach USD 588.9 million by 2021 from USD 387.7 million in 2016, growing at a CAGR of 8.7% during the forecast period.Continuous support in the form of investments and grants, and personalized medicine fueling the demand for personalized humanized rat models are some of the factors driving the growth of the rat model market. In addition to this, increase in R&D activities in pharmaceutical industries is further stimulating the market growth.......
  • Global Mycoplasma Testing Market Research Report 2017
    Published: 10-Jan-2017        Price: US 2999 Onwards        Pages: 116
    This report studies Mycoplasma Testing in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering Abbott Affymetrix Beckman Coulter/Danaher Becton Dickinson BioMerieux Bio-Rad Cepheid Diamedix/Erba DiaSorin Eiken Chemical Elitech Group Enzo B......
  • Sphingosine 1-Phosphate (S1P) Receptor Agonists -Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Sphingosine 1-Phosphate (S1P) Receptor Agonists-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Sphingosine 1-Phosphate (S1P) Receptor Agonists. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activit......
  • Sphingosine 1-Phosphate Type 1 (S1P-1) Receptor Agonists -Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Sphingosine 1-Phosphate Type 1 (S1P-1) Receptor Agonists-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Sphingosine 1-Phosphate Type 1 (S1P-1) Receptor Agonists. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other d......
  • Inositol 5'-Phosphatase (SHIP) Agonists -Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Inositol 5'-Phosphatase (SHIP) Agonists-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Inositol 5'-Phosphatase (SHIP) Agonists. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including te......
  • Insulin Like Growth Factor 1 (IGF-1) Activators -Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Insulin Like Growth Factor 1 (IGF-1) Activators-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Insulin Like Growth Factor 1 (IGF-1) Activators. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activit......
  • Insulin Like Growth Factor 2 (IGF-2) Inhibitors -Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Insulin Like Growth Factor 2 (IGF-2) Inhibitors-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Insulin Like Growth Factor 2 (IGF-2) Inhibitors. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activit......
  • Interferon Gamma Receptor (IFNGR) Binders -Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Interferon Gamma Receptor (IFNGR) Binders-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Interferon Gamma Receptor (IFNGR) Binders. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities includin......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs